Roche Pays Atavistik $70 Million Upfront for Allosteric CVRM Discovery
Atavistik Bio will use its AMPS metabolite protein screening platform to discover allosteric small molecules for cardiovascular, renal, and metabolic targets under a Roche collaboration worth up to $1.9 billion in milestones.
What changed
On 24 September 2026, Atavistik Bio announced a strategic research collaboration with Roche to discover and develop novel allosteric small molecule therapeutics for cardiovascular, renal, and metabolic (CVRM) diseases. Atavistik receives a $70 million upfront payment and may earn up to $1.9 billion in research, development, and commercial milestone payments plus tiered royalties on approved medicines from the collaboration.
Atavistik will lead discovery and research on agreed targets using its AMPS metabolite protein screening platform, which screens metabolites against proteins to find cryptic functional binding pockets on traditionally hard to drug targets. Roche takes responsibility for subsequent preclinical development, clinical trials, regulatory work, and commercialization. No clinical stage candidates were disclosed; the deal remains at discovery and research phase.
Why it matters
Large pharma continues to outsource early discovery for difficult target classes instead of building every platform internally. The upfront size signals Roche's willingness to pay for optionality on allosteric chemistry, not just a single asset. For biotech R&D leaders, the deal validates metabolite guided pocket finding as a partnerable capability distinct from structure based AI design shops.
Atavistik remains focused internally on rare hematology programs while extending AMPS into CVRM through Roche's field expertise, a split that limits execution risk for a clinical stage company.
Who is affected
Biotech BD teams pitching allosteric or cryptic pocket platforms should benchmark economics against this $70 million upfront and backloaded milestone structure. CVRM drug hunters at midsize pharma must assume Roche now has exclusive access to AMPS derived starting points on collaboration targets. Investors in AI enabled discovery should note the deal validates platform licensing, not only internal pipeline value.
What to do next
If you evaluate discovery partnerships, request whether your targets overlap Roche's stated CVRM interest areas (uncontrolled hypertension, obesity in diabetes settings, MASH, myocardial disease per Roche partnering pages summarized by trade press). Treat overlap as a competitive signal, not a legal conclusion.
What to watch
Watch for first disclosed collaboration targets or lead series entries into Roche preclinical workflows. Watch Atavistik's internal ATV-1601 Phase 1/2 readouts in hereditary hemorrhagic telangiectasia as a separate platform proof point. Watch whether Genentech sibling deals (Earendil bispecific oncology collaboration, 24 September 2026) cluster into a broader Roche external innovation push.
Sources
- Primary. Atavistik Bio, Strategic Research Collaboration with Roche (24 September 2026). Upfront, milestones, division of responsibilities, AMPS platform description.
- Secondary. Fierce Biotech, Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs (24 September 2026). Deal economics and Roche CVRM strategy context.